Blueprint Medicines Valuation
| BPMC Stock | USD 93.94 1.25 1.31% |
At this time, the firm appears to be undervalued. Blueprint Medicines Corp shows a prevailing Real Value of $105.53 per share. The current price of the firm is $93.94. Our model approximates the value of Blueprint Medicines Corp from analyzing the firm fundamentals such as Current Valuation of 5.86 B, profit margin of (0.13) %, and Return On Equity of -0.31 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Blueprint Medicines' valuation include:
Price Book 20.1006 | Enterprise Value | Enterprise Value Ebitda 304.5102 | Price Sales 11.7984 | Enterprise Value Revenue 11.5108 |
Undervalued
Today
Please note that Blueprint Medicines' price fluctuation is very steady at this time. Calculation of the real value of Blueprint Medicines Corp is based on 3 months time horizon. Increasing Blueprint Medicines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Blueprint Medicines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Blueprint Stock. However, Blueprint Medicines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 93.94 | Real 105.53 | Target 125.58 | Hype 94.05 | Naive 83.0 |
The real value of Blueprint Stock, also known as its intrinsic value, is the underlying worth of Blueprint Medicines Corp Company, which is reflected in its stock price. It is based on Blueprint Medicines' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Blueprint Medicines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Blueprint Medicines Corp helps investors to forecast how Blueprint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Blueprint Medicines more accurately as focusing exclusively on Blueprint Medicines' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Blueprint Medicines' intrinsic value based on its ongoing forecasts of Blueprint Medicines' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Blueprint Medicines' closest peers. If more than one evaluation category is relevant for Blueprint Medicines we suggest using both methods to arrive at a better estimate.
Blueprint Medicines Cash |
|
Blueprint Valuation Trend
Comparing Blueprint Medicines' enterprise value against its market capitalization is a good way to estimate the value of Blueprint Medicines Corp uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Blueprint Revenue by Product
Blueprint Medicines Total Value Analysis
Blueprint Medicines Corp is currently expected to have valuation of 5.86 B with market capitalization of 6 B, debt of 126.05 M, and cash on hands of 853.11 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Blueprint Medicines fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.86 B | 6 B | 126.05 M | 853.11 M |
Blueprint Medicines Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.07. Blueprint Medicines Corp had not issued any dividends in recent years. Based on the key indicators related to Blueprint Medicines' liquidity, profitability, solvency, and operating efficiency, Blueprint Medicines Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Blueprint Medicines Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Blueprint Medicines has an asset utilization ratio of 43.13 percent. This indicates that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that Blueprint Medicines Corp is more efficient with each dollar of assets it utilizes for everyday operations.Blueprint Medicines Ownership Allocation
Blueprint Medicines holds a total of 63.91 Million outstanding shares. The majority of Blueprint Medicines Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Blueprint Medicines Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Blueprint Medicines. Please pay attention to any change in the institutional holdings of Blueprint Medicines Corp as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Blueprint Medicines Profitability Analysis
The company reported the previous year's revenue of 508.82 M. Net Loss for the year was (67.09 M) with profit before overhead, payroll, taxes, and interest of 488.66 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Blueprint Medicines' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Blueprint Medicines and how it compares across the competition.
About Blueprint Medicines Valuation
The stock valuation mechanism determines Blueprint Medicines' current worth on a weekly basis. Our valuation model uses a comparative analysis of Blueprint Medicines. We calculate exposure to Blueprint Medicines's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Blueprint Medicines's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 488.7 M | 513.1 M | |
| Pretax Profit Margin | (0.13) | (0.14) | |
| Operating Profit Margin | (0.42) | (0.44) | |
| Net Loss | (0.13) | (0.14) | |
| Gross Profit Margin | 0.96 | 1.01 |
Blueprint Medicines Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 63.7 M |
Blueprint Medicines Current Valuation Indicators
Valuation refers to the process of determining the present value of Blueprint Medicines Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Blueprint we look at many different elements of the entity such as Blueprint's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Blueprint Medicines, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Blueprint Medicines' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Blueprint Medicines' worth.Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |